Rituximab in Treating Patients With Hodgkin's Lymphoma

Part of paid clinical trials in Stanford, California.

Sponsor
Ranjana Advani
Study ID
NCT00003820
Phase
PHASE2
Status
Completed

Conditions

  • Hodgkin Lymphoma (Category)
  • Lymphoma
  • Nodular Lymphocyte Predominant Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
3 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Rituximab — DRUG
    Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.

Study Details

Phase 2 trial to study the effectiveness of rituximab in treating patients who have lymphocyte-predominant Hodgkin's lymphoma.

Key Dates

Start date
Jan 31, 1999
Status verified
Mar 2017
Primary completion
Aug 31, 2008
Completion
Aug 31, 2008

Study Design

Enrollment
39 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Rituximab 375 mg/m2 per week
    375 mg/m2 rituximab by IV infusion weekly. The initial course of treatment is 4 weeks. Subjects who achieve an objective response or stable disease after the initial course (4 weeks) were permitted to continue additional 4-week cycles of treatment, for 3 additional courses starting every 6 months (ie, at 6; 12; and 18 months).

Primary Outcome Measure

Progression-free Survival (PFS) [ Time Frame: 5 years ]

Locations (2)

FacilityCityStateZIPSite coordinators
Stanford University Medical CenterStanfordCalifornia94305-
Stanford University School of MedicineStanfordCalifornia94305-

Find similar trials in Stanford, CA

By research site
Stanford University Medical Center· Stanford, CAStanford University School of Medicine· Stanford, CA

Related Studies